Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide combining glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to deliver superior weight loss and metabolic improvement versus single-agonist therapy, achieving 20.9% weight loss (40-50+ pounds) over 18 months with HbA1c reductions of 2.58% in type 2 diabetes—the most potent single metabolic agent currently available.

Triple mechanism: GLP-1 suppresses appetite, improves glucose sensitivity, and delays gastric emptying; GIP enhances insulin secretion response to glucose and reduces triglycerides; combined effect produces superior metabolic restoration impossible with either alone. Trials show 68.4% of participants achieved >10% weight loss versus 23% with semaglutide alone. Weekly injection protocol offers simplicity. Superior improvements in insulin secretion and fasting glucose versus semaglutide position it as next-generation obesity and diabetes therapy. Gastrointestinal side effects (nausea, constipation) are transient and dose-manageable. For individuals with obesity, type 2 diabetes, or metabolic syndrome, Tirzepatide represents the highest-efficacy metabolic peptide available.

(10mg)

Goal: Support glycemic control and weight management through dual incretin receptor activation.

Prep: Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 5.0 mg/mL).

(30mg)

Goal: Efficient management of glycemic control and metabolic parameters with high-concentration dosing.

Prep: Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 10.0 mg/mL).